NCT05984901Completed
The CAVA Multicentre Dizziness Trial
Continuous Ambulatory Vestibular Assessment (CAVA): Development of a System to Provide an Automatic Diagnosis for Vestibular Conditions
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV). The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack. The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 4 (actual)
- First submitted
- 2 May 2023
- Start date
- 1 Apr 2022
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Diseases
- Migraine
- NCT number
- NCT05984901
What you commit to
- Study type: Interventional
- Participants enrolled: 4
- From 1 Apr 2022 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has an allergy to plasters and/or medical adhesives
- Evidence of dermatitis, fragile skin, or any other condition that could be aggravated by the repeated application of skin surface adhesives
- Bilateral or second side Ménière's Disease
- Patients who meet diagnostic criteria for more than one eligible condition at time of recruitment
Other
- Pregnant or breastfeeding mothers
- Active bilateral or second side posterior canal Benign Paroxysmal Positional Vertigo
- Currently enrolled on an intervention trial (not including questionnaire-based or observational trial)
Who the study is looking for
- Age 18 and over
- Must have relevant index medical condition: Ménière's Disease, Vestibular Migraine, posterior canal Benign Paroxysmal Positional Vertigo (see section 6.3.1.2 for specific criteria)
- Experiencing episodes of true vertigo with at least 2 episodes within the preceding 4 weeks at time of consent
- The duration and nature of the vertigo is of a duration and a nature supportive of the relevant index medical condition
- Owns and able to use a telephone
- Willing to provide informed consent
- Willing to comply with the study protocol for using the CAVA device
- Willing to complete all study materials
- Adequate grasp of the English language or language used within an existing translated version of the informed consent form and patient information sheet and where hospital translators are available to provide support
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Norfolk and Norwich University Hospitals Foundation Trust Coordinator of this site? Confirm its status | Norwich | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.